Home > Insider Trading > Filing (0001455244-13-000002)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
827809	Qlt Inc	QLTI	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1369220	R Alexander Lussow	C/O Qlt Inc. 887 Great Northern Way, Suite 101 Vancouver A1 V5T 4T5	Sr. Vp, Bus. Dev. & Comm. Op.	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-05-03	90,000	$7.14	110,000	No	4	M	Direct
Common Stock	Disposition	2013-05-03	90,000	$7.85	20,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2013-05-03	90,000	$0.00	90,000	$7.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2016-05-24	No	4	M	Direct

Footnotes

Price reflects the conversion of Canadian dollars to US dollars based on the Bank of Canada nominal noon exchange rate as of the date of the reportable event.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.53 to $7.98 inclusive. The reporting person undertakes to provide to QLT Inc., any security holder of QLT Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option originally provided for vesting in 36 equal monthly installments measured from May 24, 2011. However, in connection with a change in control of QLT Inc. (as defined in the option agreement), the unvested shares under such option were accelerated and became fully exercisable on June 4, 2012.